316 related articles for article (PubMed ID: 23354978)
1. Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation.
Rinella ES; Shao Y; Yackowski L; Pramanik S; Oratz R; Schnabel F; Guha S; LeDuc C; Campbell CL; Klugman SD; Terry MB; Senie RT; Andrulis IL; Daly M; John EM; Roses D; Chung WK; Ostrer H
Hum Genet; 2013 May; 132(5):523-36. PubMed ID: 23354978
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
3. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
4. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
5. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
[TBL] [Abstract][Full Text] [Related]
6. The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.
Gal I; Gershoni Baruch R; Haber D; Dagan E; Eisenberg-Barzilai S; Zidan J; Friedman E
Fam Cancer; 2004; 3(1):11-4. PubMed ID: 15131400
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
8. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent.
Yarden RI; Friedman E; Metsuyanim S; Olender T; Ben-Asher E; Papa MZ
Breast Cancer Res Treat; 2008 Oct; 111(3):497-504. PubMed ID: 18026875
[TBL] [Abstract][Full Text] [Related]
9. Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers.
Im KM; Kirchhoff T; Wang X; Green T; Chow CY; Vijai J; Korn J; Gaudet MM; Fredericksen Z; Shane Pankratz V; Guiducci C; Crenshaw A; McGuffog L; Kartsonaki C; Morrison J; Healey S; Sinilnikova OM; Mai PL; Greene MH; Piedmonte M; Rubinstein WS; ; Hogervorst FB; Rookus MA; Collée JM; Hoogerbrugge N; van Asperen CJ; Meijers-Heijboer HE; Van Roozendaal CE; Caldes T; Perez-Segura P; Jakubowska A; Lubinski J; Huzarski T; Blecharz P; Nevanlinna H; Aittomäki K; Lazaro C; Blanco I; Barkardottir RB; Montagna M; D'Andrea E; ; Devilee P; Olopade OI; Neuhausen SL; Peissel B; Bonanni B; Peterlongo P; Singer CF; Rennert G; Lejbkowicz F; Andrulis IL; Glendon G; Ozcelik H; ; Toland AE; Caligo MA; ; Beattie MS; Chan S; ; Domchek SM; Nathanson KL; Rebbeck TR; Phelan C; Narod S; John EM; Hopper JL; Buys SS; Daly MB; Southey MC; Terry MB; Tung N; Hansen TV; Osorio A; Benitez J; Durán M; Weitzel JN; Garber J; Hamann U; ; Peock S; Cook M; Oliver CT; Frost D; Platte R; Evans DG; Eeles R; Izatt L; Paterson J; Brewer C; Hodgson S; Morrison PJ; Porteous M; Walker L; Rogers MT; Side LE; Godwin AK; Schmutzler RK; Wappenschmidt B; Laitman Y; Meindl A; Deissler H; Varon-Mateeva R; Preisler-Adams S; Kast K; Venat-Bouvet L; Stoppa-Lyonnet D; Chenevix-Trench G; Easton DF; Klein RJ; Daly MJ; Friedman E; Dean M; Clark AG; Altshuler DM; Antoniou AC; Couch FJ; Offit K; Gold B
Hum Genet; 2011 Nov; 130(5):685-99. PubMed ID: 21597964
[TBL] [Abstract][Full Text] [Related]
10. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers.
Antoniou AC; Sinilnikova OM; McGuffog L; Healey S; Nevanlinna H; Heikkinen T; Simard J; Spurdle AB; Beesley J; Chen X; ; Neuhausen SL; Ding YC; Couch FJ; Wang X; Fredericksen Z; Peterlongo P; Peissel B; Bonanni B; Viel A; Bernard L; Radice P; Szabo CI; Foretova L; Zikan M; Claes K; Greene MH; Mai PL; Rennert G; Lejbkowicz F; Andrulis IL; Ozcelik H; Glendon G; ; Gerdes AM; Thomassen M; Sunde L; Caligo MA; Laitman Y; Kontorovich T; Cohen S; Kaufman B; Dagan E; Baruch RG; Friedman E; Harbst K; Barbany-Bustinza G; Rantala J; Ehrencrona H; Karlsson P; Domchek SM; Nathanson KL; Osorio A; Blanco I; Lasa A; Benítez J; Hamann U; Hogervorst FB; Rookus MA; Collee JM; Devilee P; Ligtenberg MJ; van der Luijt RB; Aalfs CM; Waisfisz Q; Wijnen J; van Roozendaal CE; ; Peock S; Cook M; Frost D; Oliver C; Platte R; Evans DG; Lalloo F; Eeles R; Izatt L; Davidson R; Chu C; Eccles D; Cole T; Hodgson S; ; Godwin AK; Stoppa-Lyonnet D; Buecher B; Léoné M; Bressac-de Paillerets B; Remenieras A; Caron O; Lenoir GM; Sevenet N; Longy M; Ferrer SF; Prieur F; ; Goldgar D; Miron A; John EM; Buys SS; Daly MB; Hopper JL; Terry MB; Yassin Y; ; Singer C; Gschwantler-Kaulich D; Staudigl C; Hansen Tv; Barkardottir RB; Kirchhoff T; Pal P; Kosarin K; Offit K; Piedmonte M; Rodriguez GC; Wakeley K; Boggess JF; Basil J; Schwartz PE; Blank SV; Toland AE; Montagna M; Casella C; Imyanitov EN; Allavena A; Schmutzler RK; Versmold B; Engel C; Meindl A; Ditsch N; Arnold N; Niederacher D; Deissler H; Fiebig B; Suttner C; Schönbuchner I; Gadzicki D; Caldes T; de la Hoya M; Pooley KA; Easton DF; Chenevix-Trench G;
Hum Mol Genet; 2009 Nov; 18(22):4442-56. PubMed ID: 19656774
[TBL] [Abstract][Full Text] [Related]
11. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
12. Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals.
Nielsen SM; De Simone LM; Olopade OI
J Genet Couns; 2018 Dec; 27(6):1405-1410. PubMed ID: 29946849
[TBL] [Abstract][Full Text] [Related]
13. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N; Kotar K; Foulkes WD
BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population.
Liu X; Cheng R; Verbitsky M; Kisselev S; Browne A; Mejia-Sanatana H; Louis ED; Cote LJ; Andrews H; Waters C; Ford B; Frucht S; Fahn S; Marder K; Clark LN; Lee JH
BMC Med Genet; 2011 Aug; 12():104. PubMed ID: 21812969
[TBL] [Abstract][Full Text] [Related]
15. FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations.
Raskin L; Pinchev M; Arad C; Lejbkowicz F; Tamir A; Rennert HS; Rennert G; Gruber SB
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1060-5. PubMed ID: 18483326
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.
Warner E; Foulkes W; Goodwin P; Meschino W; Blondal J; Paterson C; Ozcelik H; Goss P; Allingham-Hawkins D; Hamel N; Di Prospero L; Contiga V; Serruya C; Klein M; Moslehi R; Honeyford J; Liede A; Glendon G; Brunet JS; Narod S
J Natl Cancer Inst; 1999 Jul; 91(14):1241-7. PubMed ID: 10413426
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33.
Gold B; Kirchhoff T; Stefanov S; Lautenberger J; Viale A; Garber J; Friedman E; Narod S; Olshen AB; Gregersen P; Kosarin K; Olsh A; Bergeron J; Ellis NA; Klein RJ; Clark AG; Norton L; Dean M; Boyd J; Offit K
Proc Natl Acad Sci U S A; 2008 Mar; 105(11):4340-5. PubMed ID: 18326623
[TBL] [Abstract][Full Text] [Related]
18. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
[TBL] [Abstract][Full Text] [Related]
20. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
